gastric juice protein is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-07. Numbers and descriptions here follow the published literature rather than marketing material.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
== Education == Özergin completed a B.S. (1987) and M.S. (1989) in chemical engineering at Boğaziçi University. She earned a Ph.D. in chemical engineering at University of Manchester in 1992. Özergin researched Streptomyces coelicolor antibiotic production and bioreactors. Her dissertation was titled Study of antibiotic synthesis by free and immobilised streptomyces coelicolor a3(2). Özergin's doctoral advisor was Ferda Mavituna.
deuterium Also hydrogen-2 or heavy hydrogen, and symbolized 2H or D. One of two stable isotopes of a hydrogen atom, the nucleus of which contains one proton and one neutron. Deuterium is both heavier and much less abundant in nature than the other stable isotope, known as protium (1H).
== Structure == β-acrosin demonstrates a high degree of sequence identity (70-80%) between boar, bull, rat, guinea pig, mouse, and human isoforms. There exists a somewhat similar (27-35%) sequence identity between β-acrosin and other serine proteases such as trypsin and chymotrypsin. While most serine proteases are activated through one cleavage event, proacrosin requires processing at both the N and C-terminal domains. Proacrosin is first cleaved between Arg-22 and adjacent Valine to create a 22 residue light chain, and an active protease termed α-acrosin. This light chain remains associated with the heavy chain, cross-linked through two disulfide bonds to form a heterodimer. Following these N-terminal cleavage events, three cleavages at the C-terminal domain removes 70 residues, yielding β-acrosin. Acrosin has two sites which have been identified as possible N-glycosylation sites: Asn-2 and Asn-169. The catalytic triad consists of residues His-57, Asp-102, and Ser-195. These residues are found in a binding pocket that has been termed the "S1" pocket, consistent with the naming scheme that has been adopted for other proteases. The S1 pocket regulates acrosin's specificity for Arg and Lys substrates, with a conserved Trp-215 serving as a "gatekeeper" residue for the binding site entrance.
==== Law 116, Puerto Rico ==== In 1937, Law 116 legalized sterilization in Puerto Rico. This law implemented Eugenics Boards within 32 states that oversaw compulsory sterilizations. More specifically, the Puerto Rican Eugenics Boards reviewed and confirmed petitions from the government and private entities to inflict sterilizations amongst the perceived "insane", "feeble minded", "diseased", and "dependent". The purpose of the Puerto Rican Eugenics Board was to regulate the reproductive capacities of "socially inferior" and perceived undesirable Puerto Ricans. This led the Puerto Rican Eugenics Board to approve 97 sterilizations before it was dissolved. Additionally, a large purpose of Law 116 was to further the science of eugenics and incite economic growth. Law 116 was the result of an increase of curiosity and political support for the science of eugenics. It was legitimized by the belief that Puerto Rico was a failing economy that consisted of "unfit" people that should be addressed by decreasing the population density through the means of forced sterilizations. Therefore, population control programs became institutionalized as well as federally subsidized. Funds from both the U.S. government and private investors enabled the last eugenics sterilization law passed under United States territorial jurisdiction. It also legalized state-mandated and forced sterilizations, which further exploited Puerto Ricans.
Sources: en.wikipedia.org
Even though YAN can be added into juice before fermentation, there are other ways to affect the levels of nitrogen in the juice before pressing, like the maturity of the orchard or what type of fertiliser is used. Using a fertiliser with a good amount of nitrogen will help the roots of apple trees; nitrogen fixing bacteria on the roots will be able to provide the tree with more nitrogen that will be able to make its way into the fruit. A low crop load can also yield juices with more YAN than a high crop load because the nitrogen in more concentrated in the low number of apples instead of being distributed to many apples. While a sufficient amount of YAN is good for the yeast and ensures fermentation of the sugars in the juice to alcohol, some cider makers may choose to limit nitrogen because it is the limiting factor. When the yeast are starved for nitrogen, they stop fermenting and die off. This can be desirable if cider makers prefer their cider to have some more sugar than alcohol in their cider. However, limiting YAN should be done in moderation because too little nitrogen can lead to an increase in hydrogen sulfide (H2S) production which is responsible for a rotten egg-like smell. Primary cider fermentation can be initiated by inoculating the cider must with selected yeast strains or by permitting indigenous yeast strains present on the fruit and in the cider production equipment to spontaneously commence fermentation without inoculation.
== History == Historically, ligand binding assay techniques were used extensively to quantify hormone or hormone receptor concentrations in plasma or in tissue. The ligand-binding assay methodology quantified the concentration of the hormone in the test material by comparing the effects of the test sample to the results of varying amounts of known protein (ligand). The foundations for which ligand binding assay have been built are a result of Karl Landsteiner, in 1945, and his work on immunization of animals through the production of antibodies for certain proteins. Landsteiner's work demonstrated that immunoassay technology allowed researchers to analyze at the molecular level. The first successful ligand binding assay was reported in 1960 by Rosalyn Sussman Yalow and Solomon Berson. They investigated the binding interaction for insulin and an insulin-specific antibody, in addition to developing the first radioimmunoassay (RIA) for insulin. These discoveries provided precious information regarding both the sensitivity and specificity of protein hormones found within blood-based fluids. Yalow and Berson received the Nobel Prize in Medicine as a result of their advancements. Through the development of RIA technology, researchers have been able to move beyond the use of radioactivity, and instead, use liquid- and solid-phase, competitive, and immunoradiometric assays. As a direct result of these monumental findings, researchers have continued the advancement of ligand binding assays in many facets in the fields of biology, chemistry, and the like.
=== Chemical synthesis === Synthetic taurine is obtained by the ammonolysis of isethionic acid (2-hydroxyethanesulfonic acid), which in turn is obtained from the reaction of ethylene oxide with aqueous sodium bisulfite. A direct approach involves the reaction of aziridine with sulfurous acid. In 1993, about 5000–6000 tonnes of taurine were produced for commercial purposes: 50% for pet food and 50% in pharmaceutical applications. In the laboratory, taurine can be produced by alkylation of ammonia with bromoethanesulfonate salts. Taurine can be synthesized in the laboratory from aziridines through a ring-opening reaction. The synthesis of taurine in the lab has been patented.
On 23 January, Iraq dumped 400 million US gallons (1,500,000 m3) of crude oil into the Persian Gulf, causing the largest offshore oil spill in history at that time. It was reported as a deliberate natural resources attack to keep US Marines from coming ashore (Missouri and Wisconsin had shelled Failaka Island during the war to reinforce the idea that there would be an amphibious assault attempt). About 30–40% of this came from allied raids on Iraqi coastal targets.
=== Physical therapy === Though physical therapy remedies have been scarcely documented, some therapeutic exercises are used to help manage lower back, neck, knee, and shoulder pain. There is moderate quality evidence that therapeutic exercise programs help reduce pain and improve function. Therapeutic exercises include:
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.